Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia; Barbara Reichert; Jeffrey F. Scott; Ashley N. Feneran; Jordan A. Kazakov; Kord Honda; Henry Koon; Meg R. Gerstenblith

doi:10.1007/s10147-019-01490-2

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley N. Feneran, Jordan A. Kazakov, Kord Honda, Henry Koon, Meg R. Gerstenblith

Research output: Contribution to journal › Review article › peer-review

Abstract

Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

Original language	English (US)
Pages (from-to)	1171-1181
Number of pages	11
Journal	International Journal of Clinical Oncology
Volume	24
Issue number	10
DOIs	https://doi.org/10.1007/s10147-019-01490-2
State	Published - Oct 1 2019
Externally published	Yes

Keywords

CTLA-4
Drug reactions
Immune checkpoint inhibitor
Melanoma
PD-1
Sarcoidosis-like granuloma

ASJC Scopus subject areas

Surgery
Hematology
Oncology

Access to Document

10.1007/s10147-019-01490-2

Fingerprint Dive into the research topics of 'Immune checkpoint inhibitor-induced sarcoidosis-like granulomas'. Together they form a unique fingerprint.

Cite this

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. / Rambhia, Pooja H.; Reichert, Barbara; Scott, Jeffrey F.; Feneran, Ashley N.; Kazakov, Jordan A.; Honda, Kord; Koon, Henry; Gerstenblith, Meg R.

In: International Journal of Clinical Oncology, Vol. 24, No. 10, 01.10.2019, p. 1171-1181.

Research output: Contribution to journal › Review article › peer-review

@article{126db2ee9db841e4a8126cbd2e606540,

title = "Immune checkpoint inhibitor-induced sarcoidosis-like granulomas",

abstract = "Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.",

keywords = "CTLA-4, Drug reactions, Immune checkpoint inhibitor, Melanoma, PD-1, Sarcoidosis-like granuloma",

author = "Rambhia, {Pooja H.} and Barbara Reichert and Scott, {Jeffrey F.} and Feneran, {Ashley N.} and Kazakov, {Jordan A.} and Kord Honda and Henry Koon and Gerstenblith, {Meg R.}",

year = "2019",

month = oct,

day = "1",

doi = "10.1007/s10147-019-01490-2",

language = "English (US)",

volume = "24",

pages = "1171--1181",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "10",

}

TY - JOUR

T1 - Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

AU - Rambhia, Pooja H.

AU - Reichert, Barbara

AU - Scott, Jeffrey F.

AU - Feneran, Ashley N.

AU - Kazakov, Jordan A.

AU - Honda, Kord

AU - Koon, Henry

AU - Gerstenblith, Meg R.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

AB - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

KW - CTLA-4

KW - Drug reactions

KW - Immune checkpoint inhibitor

KW - Melanoma

KW - PD-1

KW - Sarcoidosis-like granuloma

UR - http://www.scopus.com/inward/record.url?scp=85069503866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069503866&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01490-2

DO - 10.1007/s10147-019-01490-2

M3 - Review article

C2 - 31321613

AN - SCOPUS:85069503866

VL - 24

SP - 1171

EP - 1181

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 10

ER -